Skip to main content

Table 1 Baseline characteristics (N = 74)

From: Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Characteristics Overall anti-PD-1/TA alone (N = 32) anti-PD-1/TA + SBRT (N = 42) P
No. of patients (%)
Age, median (range) 53 (18–83) 53 (18–83) 53 (24–75) 0.571
Sex     0.732
 Male 54 (73.0) 24 (75.0) 30 (71.4)  
 Female 20 (27.0) 8 (25.0) 12 (28.6)  
Histology     0.755
 Clear cell 50 (67.6) 21 (65.6) 29 (69.0)  
 Non-clear cell 24 (32.4) 11 (34.4) 13 (31.0)  
ECOG     0.253
 0–1 38 (51.4) 14 (43.8) 24 (57.1)  
  >1 36 (48.6) 18 (56.3) 18 (42.9)  
IMDC risk group     0.461
 Favorable 16 (21.6) 5 (15.6) 11 (26.2)  
 Intermediate 43 (58.1) 21 (65.6) 22 (52.4)  
 Poor 15 (20.3) 6 (18.8) 9 (21.4)  
Brain metastasis 2 (2.7) 1 (3.1) 1 (2.4) 1.000
Bone metastasis 18 (24.3) 4 (12.5) 14 (33.3) 0.039
Liver metastasis 9 (12.2) 6 (18.8) 3 (7.1) 0.248
Synchronous metastasis 34 (45.9) 14 (43.8) 20 (47.6) 0.741
Oligometastasis 17 (23.0) 5 (15.6) 12 (28.6) 0.190
Nephrectomy 63 (85.1) 27 (84.4) 36 (85.7) 1.000
No. of prior therapies     1.000
 1 63 (85.1) 27 (84.4) 36 (85.7)  
  >1 11 (14.9) 5 (15.6) 6 (14.3)